We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cognizant Technology Solutions Corporation (CTSH) - free report >>
Experian PLC (EXPGY) - free report >>
TransUnion (TRU) - free report >>
Innovator International Developed Power Buffer ETF - November (INOV) - free report >>
Image: Bigstock
TransUnion Inks Deal to Buy Rubixis, Boosts Healthcare Suite
TransUnion (TRU - Free Report) recently announced that it has inked a deal to purchase Rubixis, a healthcare revenue cycle solutions company, which assists healthcare providers in collecting reimbursements from insurance payers.
Rubixis specializes in the management of denials and underpayments. It helps healthcare providers earn reimbursement efficiently by offering a robust software platform which leverages analytics, workflow tools and/or complementary accounts receivable outsourcing services.
So, addition of Rubixis is expected to place TransUnion as a competitive player in the post-discharge revenue recovery market. Dave Wojczynski, president of TransUnion Healthcare stated “together, we will offer powerful data, analytics and capabilities that will benefit providers by helping to maximize reimbursement and ultimately improve the patient financial experience.”
The deal is expected to be closed following the fulfillment of customary closing conditions.
Bottom Line
With the healthcare industry continuing to struggle with claims denial write-offs, which have increased persistently over the past decade, we believe the deal to acquire Rubixis is a prudent business move by TransUnion.
Notably, the company has been active in strengthening its Healthcare’s Revenue Protection solutions. The latest move follows the recent purchase of Healthcare Payment Specialists and the appointment of Dave Wojczynski as the president of TransUnion Healthcare.
We believe that with moves like these, TransUnion is likely to better compete with the likes of Experian’s (EXPGY - Free Report) Experian Health, Inovalon Holdings (INOV - Free Report) and Cognizant Technology Solutions Corporation’s (CTSH - Free Report) Trizetto in the healthcare space.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>